

U.S.S.N. 09/625,963

Filed: July 26, 2000

CLEAN VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121

Clean Version of Amended Claims
Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

C/SUB 1 1. (Three times amended) A peptide having at least 9 but fewer than 100 amino acids, which peptide comprises the amino acid sequence RMFPNAPYL (SEQ ID NO:1).

4. A peptide according to claim 1 wherein the peptide is capable of binding to HLA-A0201.

5. A peptide according to claim 4 wherein when bound to HLA-A0201 the peptide-bound HLA-A0201 is capable of eliciting the production of a cytotoxic T lymphocyte (CTL) which recognises a cell which aberrantly expresses a polypeptide comprising the given amino acid sequence.

7. (Twice Amended) A peptide consisting of the amino acid sequence RMFPNAPYL (SEQ ID NO:1).

15. (Twice Amended) A pharmaceutical composition comprising the peptide of Claim 1 and a pharmaceutically acceptable carrier.

C2 SUB 2 44. The peptide of claim 1 consisting of from 9 to 12 amino acids.

45. The peptide of claim 1 which is capable of being processed by an antigen presenting cell so that a fragment is produced which is able to bind to HLA-A0201.